| A RANDOMIZED, OPEN-LABEL, MULTI-CENTER PHASE II STUDY TO COMPARE BEVACIZUMAB PLUS SORAFENIB VERSUS SORAFENIB FOR THE THIRD-LINE TREATMENT OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (NCT02330783) | |
| Guo, Jun; Sheng, Xinan; Chi, Zhihong; Cui, Chuanliang; Si, Lu; Li, Siming; Mao, Lili; Lian, Bin; Tang, Bixia; Yan, Xieqiao | |
| 2015 | |
| 卷号 | 35 |
| 期号 | 7 |
| 会议录 | ANTICANCER RESEARCH
 |
| 语种 | 英语 |
| URL标识 | 查看原文 |
| ISSN号 | 0250-7005 |
| 内容类型 | 会议论文 |
| URI标识 | http://www.corc.org.cn/handle/1471x/4870730 |
| 专题 | 复旦大学上海医学院 |
| 推荐引用方式 GB/T 7714 | Guo, Jun,Sheng, Xinan,Chi, Zhihong,et al. A RANDOMIZED, OPEN-LABEL, MULTI-CENTER PHASE II STUDY TO COMPARE BEVACIZUMAB PLUS SORAFENIB VERSUS SORAFENIB FOR THE THIRD-LINE TREATMENT OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (NCT02330783)[C]. 见:. |
| 个性服务 |
| 查看访问统计 |
| 相关权益政策 |
| 暂无数据 |
| 收藏/分享 |
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
修改评论